LifeSpan Vision Ventures

EpiBone, Inc. is a biotechnology company based in Brooklyn, New York, focused on developing advanced solutions for bone and cartilage repair. Founded in 2013, EpiBone utilizes patient-specific scans and their own stem cells to create customized bone grafts, which are cultivated in a bioreactor to facilitate growth. The company aims to improve skeletal repair and enhance bone formation and regeneration through its innovative technologies. EpiBone's lead product, a living 3D bone graft, successfully completed its Phase I/IIa clinical trial in August 2023. Additionally, the company is advancing its cartilage repair pipeline, which includes an allogeneic osteochondral plug that received Investigational New Drug approval in July 2023, and an injectable cartilage filler, partly funded by the Department of Defense. Through these developments, EpiBone seeks to revolutionize orthopedic repair and provide patients with more effective treatment options.

LIfT BioSciences is a biotechnology company based in London, England, founded in 2016. The company specializes in a novel allogeneic innate immuno-cell therapy platform known as Neutrophil Only Leukocyte Infusion Therapy (N-LIfT). This platform enables the large-scale production of Immunomodulatory Alpha Neutrophils (IMANs) derived from induced pluripotent stem cells (iPSCs) for various therapeutic applications. LIfT BioSciences focuses on developing CAR neutrophil cell therapies that address the limitations of existing treatments for solid tumors. These therapies work by directly attacking tumors and indirectly enhancing the immune response, effectively transforming the tumor microenvironment to recruit additional immune cells for a more robust and lasting attack on the cancer. By employing proprietary enhancement media and genetic engineering, LIfT BioSciences aims to significantly increase the cancer-fighting capabilities of these engineered cells, potentially providing patients with greatly improved therapeutic outcomes.

Remedium Bio is a Boston-based gene therapy company dedicated to developing curative treatments for various debilitating conditions. The company employs a modular approach to research and development, utilizing established technologies in innovative ways to address well-understood disease mechanisms. By focusing on clinically validated molecules and targeted treatment strategies, Remedium Bio aims to create effective therapies for conditions within rheumatology, endocrinology, and neurology. Its pipeline includes promising gene therapy candidates designed to tackle a wide range of diseases, including immune and age-related disorders.

Immunis a private biotechnology company developing a novel treatment for age and disease-related immune decline.

Senisca is a biotech start-up. They propose to create a new generation of oligonucleotide-based interventions to rewind the clock in old cells and target diseases and cosmetic signs of aging. They provide molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence.

Bolden Therapeutics is a biotechnology company developing first-in-class therapeutics to treat central nervous system diseases.

NaNotics is a medical platform focused on treating autoimmune disorders and solid tumor malignancies through innovative nanotechnology. The platform utilizes nanoparticles that are injected into the bloodstream to target and remove specific disease-causing molecules efficiently and safely. This approach enables physicians to offer patients a novel, potent, and highly safe treatment option. By eliminating particular circulating molecular signals that contribute to illness progression, NaNotics aims to enhance the efficacy of disease management and improve patient outcomes.

Matter Bio is a biotechnology company dedicated to preserving genome integrity and enhancing longevity through the preservation of DNA information. The company aims to address the critical issue of information loss in the genome by assembling a team of expert scientists and executives. By focusing on mutation reversal, Matter Bio seeks to empower patients with the potential to improve their health and extend their lifespan. Through its innovative research services, the company strives to advance the understanding and application of genetic preservation techniques.

Rejuvenation Technologies Inc. is a biotechnology company based in Mountain View, California, focused on developing nucleoside-modified telomerase reverse transcriptase messenger RNA to extend telomeres and promote human health. The company's innovative approach involves delivering a telomere extender that encodes telomerase reverse transcriptase, which transiently boosts telomerase activity in cells. This technology aims to enhance the proliferative capacity of cells, potentially addressing age-related diseases and conditions in various medical fields, including hepatic, pulmonary, and immunology. Additionally, Rejuvenation Technologies offers a range of cell therapies that encompass tissue engineering, cell transplants, skin grafts, immunotherapy, and regenerative medicine. Established in 2016, the company is dedicated to advancing solutions in regenerative health.

Integrated Biosciences focuses on developing innovative therapeutics aimed at combating age-related diseases. Founded on research from prestigious institutions such as Harvard, MIT, and UCSB, the company has made significant strides in the field, including the first AI-driven discovery of anti-aging drug candidates and the introduction of a novel structural class of antibiotics in six decades. By leveraging synthetic biology and machine learning, Integrated Biosciences seeks to control cellular stress responses, facilitating advancements in cellular rejuvenation and empowering medical professionals with next-generation treatment options.